MedTrace Logo

NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization

NCT00356954 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2006-11-27

No results posted yet for this study

Summary

The contrast induced nephropathy (CIN) has been known to be associated with significant clinical and economic consequences. Many studies were performed to find the pathophysiology and preventive measures for CIN. But the results were somewhat frustrating. Recently, it has been reported that the N-acetylcysteine and ascorbic acid might have preventive effects for CIN by their antioxidant effects.There have been no study to compare these two antioxidant.

Conditions

Interventions

DRUG

N-acetylcystein

DRUG

ascorbic acid

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Sang-Ho Jo, M.D. · Seoul National University Hospital, Department of Internal Medicine/ Cardiovascular Center, Hallym University Sacred Heart Hospital

  • Bon-Kwon Koo, M.D., Ph.D. · Seoul National University Hospital, Department of Internal Medicine/ Cardiovascular Center

  • Hyo-Soo Kim, M.D.,Ph.D. · Seoul National University Hospital, Department of Internal Medicine/ Cardiovascular Center

  • Byung-Hee Oh, M.D., Ph.D. · Seoul National University Hospital, Department of Internal Medicine/ Cardiovascular Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2006-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00356954 on ClinicalTrials.gov